Skip to main content
SpringerLink
Log in

Risk of PI3K inhibitor-related cutaneous AEs

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Wang Y, et al. Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol-3-kinase inhibitors: A systematic review and meta-analysis of randomized controlled trials Cancer Medicine : 22 Aug 2022. Available from: URL: https://doi.org/10.1002/cam4.5153

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Risk of PI3K inhibitor-related cutaneous AEs. Reactions Weekly 1921, 11 (2022). https://doi.org/10.1007/s40278-022-22005-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-22005-3

Search

Navigation